Matrix Global Advisors: “Payer Strategies to Promote Biosimilar Utilization”
April 11, 2016
Biologics are among the most expensive drugs available and represent a large and increasing share of U.S. drug spending. Biosimilars,...
Filter by:
Biosimilars
Filter by Year:Clear Filters- Research
- Biosimilars
- Drug Abuse Prevention
- Drug Adherence Programs
- Drug Cost Management
- Drug Coupons & Assistance Programs
- Drug Coverage Mandates
- Drug Price Negotiations & Rebates
- Employers, Unions, & Insurers
- FEHB Program
- Formulary Design
- Fraud, Waste, & Abuse
- Generic Drug Utilization
- Health Insurance Marketplace (ACA)
- Home Delivery of Drugs
- Medicaid
- Medicare Part D
- Patient Cost Sharing
- Pharmacy Networks
- Pharmacy Reimbursement & Contracting
- REMS Management
- Specialty Benefit Design
- Specialty Pharmacies
- Specialty Pharmacy Networks
- TRICARE
PBMs: Generating Savings for Plan Sponsors and Consumers
February 04, 2016
Pharmacy Benefit Managers (PBMs) now implement prescription drug benefits for some 266 million Americans who have health insurance from a...